Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Epidermal growth factor receptor (EGFR) is a key target in cancer therapy due to its frequent dysregulation in various malignancies.
• Current EGFR inhibitors like gefitinib and erlotinib are effective but face clinical resistance, necessitating new therapeutic strategies.

Purpose of the Study:

• To review recent advancements (last 5 years) in the development of small molecule EGFR inhibitors.
• To focus on inhibitors utilizing the quinazoline core scaffold.
• To discuss structure-activity relationships (SARs) of these novel inhibitors.

Main Methods:

• Literature review of scientific publications and patents.
• Classification of EGFR inhibitors based on quinazoline scaffolds (4-anilinoquinazolines and 4-nonanilininoquinazolines).
• Analysis of biological data and SARs for identified compounds.

Main Results:

• Identification and characterization of diverse small molecule EGFR inhibitors based on quinazoline scaffolds.
• Detailed discussion of biological activity and SARs for 4-anilinoquinazolines and 4-nonanilininoquinazolines.
• Highlighting potential candidates for overcoming EGFR inhibitor resistance.

Conclusions:

• Quinazoline-based small molecules represent a promising class of EGFR inhibitors.
• Understanding SARs is crucial for designing potent and selective inhibitors to combat cancer and resistance.
• Continued research in this area is vital for developing improved cancer therapeutics.